Respiratory syncytial virus (RSV) infections in adults: Current trends and recommendations for prevention–a global challenge from a local perspective

DURUSU TANRIÖVER M., AZAP A., Cakir Edis E., Ozger H. S., Pullukcu H., SÖNMEZER M. Ç., ...Daha Fazla

Human Vaccines and Immunotherapeutics, cilt.21, sa.1, 2025 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 21 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1080/21645515.2025.2514357
  • Dergi Adı: Human Vaccines and Immunotherapeutics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, Directory of Open Access Journals
  • Anahtar Kelimeler: adult, influenza like illness, low- and middle- income countries, lower respiratory tract infections (LRTI), preventive medicine, Respiratory syncytial virus, severe acute respiratory infection, vaccines
  • Ankara Üniversitesi Adresli: Evet

Özet

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) and a major health threat especially for children and older adults. Epidemiological data reveal that RSV-associated global mortality rates in individuals aged ≥ 70 years exceeded those in children aged < 5 years in 2019. Although effective interventions have decreased RSV-related deaths in children aged < 5 years over time, RSV appears increasingly significant issue for the elderly and adults with underlying health conditions. Furthermore, there is currently no specific treatment for RSV infections in adults, highlighting the importance of prevention. Recently, three vaccines (RSVPreF3, RSVpreF, and mRNA-1345) have been approved for adults to date. In this article, we aimed to review the characteristics of RSV infections in adults and the evidence on the safety and efficacy of RSV vaccines, with a glimpse of the current situation in Türkiye- one of the low- and middle- income countries (LMICs).